أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

primecrown 2010 limited - salmeterol xinafoate; fluticasone propionate - inhalation powder, pre-dispensed - 50/250mcg microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

primecrown 2010 limited - salmeterol xinafoate; fluticasone propionate - inhalation powder, pre-dispensed - 50/500mcg microgram(s) - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25/250 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

pco manufacturing ltd. - salmeterol xinafoate; fluticasone propionate - pressurised inhalation, suspension - 25/50 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

أيرلندا - الإنجليزية - HPRA (Health Products Regulatory Authority)

lexon (uk) ltd - salmeterol xinafoate; fluticasone propionate - powder for inhalation - 50/500 microgram(s)/dose - adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics; salmeterol and fluticasone

أرمينيا - الإنجليزية - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo wellcome production - salmeterol (salmeterol xinafoate), fluticasone (fluticasone propionate) - powder for inhalation - 50mcg+100mcg

أرمينيا - الإنجليزية - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo wellcome production - salmeterol (salmeterol xinafoate), fluticasone (fluticasone propionate) - powder for inhalation - 50mcg+500mcg

أرمينيا - الإنجليزية - Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում

glaxo wellcome production - salmeterol (salmeterol xinafoate), fluticasone (fluticasone propionate) - powder for inhalation - 50mcg+250mcg

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

cipla australia pty ltd - salmeterol xinafoate, quantity: 0.0725 mg (equivalent: salmeterol, qty 0.05 mg); fluticasone propionate, quantity: 0.5 mg - inhalation, powder for - excipient ingredients: lactose monohydrate - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include: ?patients on effective maintenance doses of long-acting beta-2 agonists and inhaled corticosteroids,?patients who are symptomatic on current inhaled corticosteroid therapy,for the symptomatic treatment of patients with severe copd (fev1 <50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. seroflo ciphaler 500/50 is not indicated for the initiation of bronchodilator therapy in copd.

أستراليا - الإنجليزية - Department of Health (Therapeutic Goods Administration)

glaxosmithkline australia pty ltd - fluticasone propionate, quantity: 50 microgram/actuation; salmeterol xinafoate, quantity: 36.3 microgram/actuation (equivalent: salmeterol, qty 25 microgram/actuation) - inhalation, pressurised - excipient ingredients: norflurane - for the regular treatment of asthma, where the use of a combination product is appropriate. this may include:,*patients on effective maintenance doses of long-acting beta-2-agonists and inhaled corticosteroids.,*patients who are symptomatic on current inhaled corticosteroid therapy.,*initiation of maintenance therapy in those patients with moderate persistent asthma not adequately controlled on "as needed" reliever medication, and who have moderate/severe airway limitation and daily symptoms requiring medication every day (see clinical trials).,for the symptomatic treatment of patients with severe copd (fev1<50% predicted normal) and a history of repeated exacerbations who have significant symptoms despite regular beta-2 agonist bronchodilator therapy. pavtide is not indicated for the initiation of bronchodilator therapy in copd.